An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
Alkaloids extracted from various species of Cinchona.
Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.
Drug metabolizing enzymes which oxidize methyl ethers. Usually found in liver microsomes.
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
A quinolizidine alkaloid isolated from several FABACEAE including LUPINUS; SPARTIUM; and CYTISUS. It has been used as an oxytocic and an anti-arrhythmia agent. It has also been of interest as an indicator of CYP2D6 genotype.
An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.

Transport of fluid by lens epithelium. (1/618)

We report for the first time that cultured lens epithelial cell layers and rabbit lenses in vitro transport fluid. Layers of the alphaTN4 mouse cell line and bovine cell cultures were grown to confluence on permeable membrane inserts. Fluid movement across cultured layers and excised rabbit lenses was determined by volume clamp (37 degrees C). Cultured layers transported fluid from their basal to their apical sides against a pressure head of 3 cmH2O. Rates were (in microliter. h-1. cm-2) 3.3 +/- 0.3 for alphaTN4 cells (n = 27) and 4.7 +/- 1.0 for bovine layers (n = 6). Quinidine, a blocker of K+ channels, and p-chloromercuribenzenesulfonate and HgCl2, inhibitors of aquaporins, inhibited fluid transport. Rabbit lenses transported fluid from their anterior to their posterior sides against a 2.5-cmH2O pressure head at 10.3 +/- 0.62 microliter. h-1. lens-1 (n = 5) and along the same pressure head at 12.5 +/- 1.1 microliter. h-1. lens-1 (n = 6). We calculate that this flow could wash the lens extracellular space by convection about once every 2 h and therefore might contribute to lens homeostasis and transparency.  (+info)

Effects of dauricine, quinidine, and sotalol on action potential duration of papillary muscles in vitro. (2/618)

AIM: To compare the characteristics of dauricine, sotalol, and quinidine on action potential duration (APD). METHODS: Using intracellular microelectrode method to record APD in guinea pig papillary muscles. RESULTS: Dauricine 20 mumol.L-1 prolonged action potential at 90% repolarization, the percent of APD prolongation were 22 +/- 8, 11 +/- 6, 9 +/- 5, 7 +/- 5, 6 +/- 3, 4.3 +/- 2.8, 4.5 +/- 2.8 at the cycle lengths of 200-2000 ms, dauricine became more effective in lengthening APD at short cycle lengths. The effect of dauricine on prolonging APD exhibited normal use-dependence, whereas quinidine 1 mumol.L-1 and sotalol 10 mumol.L-1 were less effective in lengthening APD at short cycle lengths. The effect of quinidine and sotalol on APD exhibited reverse use-dependence. CONCLUSSION: The effect of dauricine on APD depends on activation frequency.  (+info)

In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. (3/618)

The aim of this study was to evaluate the (3S)-3-hydroxylation and the N-oxidation of quinidine as biomarkers for cytochrome P-450 (CYP)3A4 activity in human liver microsome preparations. An HPLC method was developed to assay the metabolites (3S)-3-hydroxyquinidine (3-OH-Q) and quinidine N-oxide (Q-N-OX) formed during incubation with microsomes from human liver and from Saccharomyces cerevisiae strains expressing 10 human CYPs. 3-OH-Q formation complied with Michaelis-Menten kinetics (mean values of Vmax and Km: 74.4 nmol/mg/h and 74.2 microM, respectively). Q-N-OX formation followed two-site kinetics with mean values of Vmax, Km and Vmax/Km for the low affinity isozyme of 15.9 nmol/mg/h, 76.1 microM and 0.03 ml/mg/h, respectively. 3-OH-Q and Q-N-OX formations were potently inhibited by ketoconazole, itraconazole, and triacetyloleandomycin. Isozyme specific inhibitors of CYP1A2, -2C9, -2C19, -2D6, and -2E1 did not inhibit 3-OH-Q or Q-N-OX formation, with Ki values comparable with previously reported values. Statistically significant correlations were observed between CYP3A4 content and formations of 3-OH-Q and Q-N-OX in 12 human liver microsome preparations. Studies with yeast-expressed isozymes revealed that only CYP3A4 actively catalyzed the (3S)-3-hydroxylation. CYP3A4 was the most active enzyme in Q-N-OX formation, but CYP2C9 and 2E1 also catalyzed minor proportions of the N-oxidation. In conclusion, our studies demonstrate that only CYP3A4 is actively involved in the formation of 3-OH-Q. Hence, the (3S)-3-hydroxylation of quinidine is a specific probe for CYP3A4 activity in human liver microsome preparations, whereas the N-oxidation of quinidine is a somewhat less specific marker reaction for CYP3A4 activity, because the presence of a low affinity enzyme is demonstrated by different approaches.  (+info)

Pseudo second degree atrioventricular block with bradycardia. Successful treatment with quinidine. (4/618)

Pseudo second degree atrioventricular block resulting from blocked His premature beats was successfully treated with quinidine. The diagnosis was proved by His bundle electrogam which showed both blocked and conducted His premature beats. The blocked His prematures produced second degree atrioventricular block by making the atrioventricular junction refractory. Quinidine abolished both conducted and blocked His extrasystoles. There has been no recurrence of arrhythmia during a one-year follow-up.  (+info)

Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. (5/618)

In the present study, functional characteristics of organic cation transporter (OCTN)1, which was cloned as the pH-dependent tetraethylammonium (TEA) transporter when expressed in mammalian human embryonic kidney (HEK)293 cells, were further investigated using Xenopus oocytes as well as HEK293 cells as gene expression systems. When OCTN1-derived complementary RNA was injected into Xenopus oocytes, pH-dependent transport of [14C]TEA was observed as the same in HEK293 cells. In contrast, a replacement of sodium ions with potassium ions in the surrounding medium did not cause any change in [14C]TEA uptake in Xenopus oocytes expressed with OCTN1. In addition, when OCTN1 was expressed in HEK293 cells, efflux of TEA from the cells was pH dependent, with an accelerated rate at acidic external medium pH. Accordingly, membrane potential or sodium ions are suggested to have no influence on [14C]TEA transport and the transport activity of OCTN1 is directly affected by pH itself. Furthermore, addition of the unlabeled TEA in external medium enhanced the efflux of preloaded [14C]TEA. These observations suggest that OCTN1 is a pH-dependent and bidirectional TEA transporter. OCTN1-mediated [14C]TEA uptake was inhibited by various organic cations such as cimetidine, procainamide, pyrilamine, quinidine, quinine, and verapamil. In addition, uptakes of cationic compounds such as [3H]pyrilamine, [3H]quinidine, and [3H]verapamil and zwitterionic L-[3H]carnitine were increased by expression of OCTN1 in Xenopus oocytes. Accordingly, OCTN1 was functionally demonstrated to be a multispecific and pH-dependent organic cation transporter, which presumably functions as a proton/organic cation antiporter at the renal apical membrane and other tissues.  (+info)

Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. (6/618)

We investigated effects of a novel cardioprotective drug, JTV-519 (4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahy dro-1,4-benzothiazepine monohydrochloride) on membrane currents of guinea pig ventricular myocytes by whole-cell voltage and current clamp methods. The fast Na+ current (iNa) was activated by ramp pulses from various holding potentials of -90, -80 or -60 mV to 10 mV with various intervals. At 0.2 Hz, JTV-519 inhibited iNa in a concentration-dependent manner with an IC50 of approximately 1.2 and 2 microM at the holding potential of -60 and -90 mM, respectively, implicating a voltage-dependent block. Increasing the pulse frequency from 1 to 2 or 3.3 Hz in the presence of 1 microM JTV-519 shortened the time-course and increased the level of iNa block, indicating a frequency-dependent block. The time-course of iNa blocking by JTV-519 was slower than that of lidocaine and similar to that of quinidine. Ca2+ current (iCa) and the inwardly rectifying K+ current (iK1) were also inhibited by JTV-519. JTV-519 decreased the duration and the height of the plateau of the action potential. We conclude that JTV-519 has frequency- and voltage-dependent blocking effects on iNa as well as inhibition of iCa and iK1.  (+info)

Alkalinization-induced K+ current of the mouse megakaryocyte. (7/618)

We have recently found that mouse megakaryocytes responded to extracellular alkalinization to pH > 8.0, generating a K+ current under voltage-clamped conditions with the whole cell recording mode of the patch-clamp technique. The purpose of this study was to physiologically and pharmacologically characterize the alkaline-dependent K+ conductance of the megakaryocyte membrane. The alkalinization-induced K+ current (I(ALK)) did not seem to be Ca2+-dependent since I(ALK) was allowed to be generated under intracellularly Ca2+-buffered conditions with 10 mM EGTA, which completely prevented the generation of caffeine-induced Ca2+-activated currents of mouse megakaryocytes; and no [Ca2+]i elevation was evoked by the alkalinization protocol in contrast to a significant increase in [Ca2+]i in response to caffeine when [Ca2+]i was measured with a fura 2 ratiometry. I(ALK) was strongly suppressed with tetraethylammonium (TEA), 4-aminopyridine (4-AP) and streptomycin (SM), but was completely resistant to quinidine (QND). The values of IC50 for the suppression of I(ALK) with TEA, 4-AP and SM were 5.6, 0.47 and 1.5 mM, respectively. Voltage-gated K+ currents (I(K)) of the same megakaryocyte preparation were weakly suppressed with TEA and 4-AP, while they were significantly suppressed with either SM or QND. These results suggest that mouse megakaryocytes possess K+ conductance that was activated by extracellular alkalinization and that probably differs from conventional K+ conductance in its pharmacological properties.  (+info)

Enhancing effects of salicylate on tonic and phasic block of Na+ channels by class 1 antiarrhythmic agents in the ventricular myocytes and the guinea pig papillary muscle. (8/618)

OBJECTIVE: To study the interaction between salicylate and class 1 antiarrhythmic agents. METHODS: The effects of salicylate on class 1 antiarrhythmic agent-induced tonic and phasic block of the Na+ current (INa) of ventricular myocytes and the upstroke velocity of the action potential (Vmax) of papillary muscles were examined by both the patch clamp technique and conventional microelectrode techniques. RESULTS: Salicylate enhanced quinidine-induced tonic and phasic block of INa at a holding potential of -100 mV but not at a holding potential of -140 mV; this enhancement was accompanied by a shift of the hinfinity curve in the presence of quinidine in a further hyperpolarized direction, although salicylate alone did not affect INa. Salicylate enhanced the tonic and phasic block of Vmax induced by quinidine, aprindine and disopyramide but had little effect on that induced by procainamide or mexiletine; the enhancing effects were related to the liposolubility of the drugs. CONCLUSIONS: Salicylate enhanced tonic and phasic block of Na+ channels induced by class 1 highly liposoluble antiarrhythmic agents. Based on the modulated receptor hypothesis, it is probable that this enhancement was mediated by an increase in the affinity of Na+ channel blockers with high lipid solubility to the inactivated state channels.  (+info)

Quinidine is a Class IA antiarrhythmic medication that is primarily used to treat and prevent various types of cardiac arrhythmias (abnormal heart rhythms). It works by blocking the rapid sodium channels in the heart, which helps to slow down the conduction of electrical signals within the heart and stabilize its rhythm.

Quinidine is derived from the bark of the Cinchona tree and has been used for centuries as a treatment for malaria. However, its antiarrhythmic properties were discovered later, and it became an important medication in cardiology.

In addition to its use in treating arrhythmias, quinidine may also be used off-label for other indications such as the treatment of nocturnal leg cramps or myasthenia gravis. It is available in various forms, including tablets and injectable solutions.

It's important to note that quinidine has a narrow therapeutic index, meaning that there is only a small difference between an effective dose and a toxic one. Therefore, it must be carefully monitored to ensure that the patient is receiving a safe and effective dose. Common side effects of quinidine include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as visual disturbances, headache, and dizziness. More serious side effects can include QT prolongation, which can lead to dangerous arrhythmias, and hypersensitivity reactions.

Quinine is defined as a bitter crystalline alkaloid derived from the bark of the Cinchona tree, primarily used in the treatment of malaria and other parasitic diseases. It works by interfering with the reproduction of the malaria parasite within red blood cells. Quinine has also been used historically as a muscle relaxant and analgesic, but its use for these purposes is now limited due to potential serious side effects. In addition, quinine can be found in some beverages like tonic water, where it is present in very small amounts for flavoring purposes.

Procainamide is an antiarrhythmic medication used to treat various types of irregular heart rhythms (arrhythmias), such as atrial fibrillation, atrial flutter, and ventricular tachycardia. It works by prolonging the duration of the cardiac action potential and decreasing the slope of the phase 0 depolarization, which helps to stabilize the heart's electrical activity and restore a normal rhythm.

Procainamide is classified as a Class Ia antiarrhythmic drug, according to the Vaughan Williams classification system. It primarily affects the fast sodium channels in the heart muscle cells, reducing their availability during depolarization. This results in a decreased rate of impulse generation and conduction velocity, which can help to suppress abnormal rhythms.

The medication is available as an oral formulation (procainamide hydrochloride) and as an injectable solution for intravenous use. Common side effects of procainamide include nausea, vomiting, diarrhea, headache, and dizziness. Procainamide can also cause a lupus-like syndrome, characterized by joint pain, skin rashes, and other autoimmune symptoms, in some patients who take the medication for an extended period.

It is essential to monitor procainamide levels in the blood during treatment to ensure that the drug is within the therapeutic range and to minimize the risk of adverse effects. Healthcare providers should also regularly assess patients' renal function, as procainamide and its active metabolite, N-acetylprocainamide (NAPA), are primarily excreted by the kidneys.

Anti-arrhythmia agents are a class of medications used to treat abnormal heart rhythms or arrhythmias. These drugs work by modifying the electrical activity of the heart to restore and maintain a normal heart rhythm. There are several types of anti-arrhythmia agents, including:

1. Sodium channel blockers: These drugs slow down the conduction of electrical signals in the heart, which helps to reduce rapid or irregular heartbeats. Examples include flecainide, propafenone, and quinidine.
2. Beta-blockers: These medications work by blocking the effects of adrenaline on the heart, which helps to slow down the heart rate and reduce the force of heart contractions. Examples include metoprolol, atenolol, and esmolol.
3. Calcium channel blockers: These drugs block the entry of calcium into heart muscle cells, which helps to slow down the heart rate and reduce the force of heart contractions. Examples include verapamil and diltiazem.
4. Potassium channel blockers: These medications work by prolonging the duration of the heart's electrical cycle, which helps to prevent abnormal rhythms. Examples include amiodarone and sotalol.
5. Digoxin: This drug increases the force of heart contractions and slows down the heart rate, which can help to restore a normal rhythm in certain types of arrhythmias.

It's important to note that anti-arrhythmia agents can have significant side effects and should only be prescribed by a healthcare professional who has experience in managing arrhythmias. Close monitoring is necessary to ensure the medication is working effectively and not causing any adverse effects.

Cytochrome P-450 CYP2D6 is a specific isoenzyme belonging to the Cytochrome P-450 (CYP) family of enzymes, which are primarily located in the liver and play a crucial role in the metabolism of various drugs and xenobiotics. The term "P-450" refers to the absorption spectrum of these enzymes when they are combined with carbon monoxide, exhibiting a peak absorbance at 450 nanometers.

CYP2D6 is involved in the metabolism of approximately 20-25% of clinically prescribed drugs, including many antidepressants, neuroleptics, beta-blockers, opioids, and antiarrhythmics. This enzyme can demonstrate genetic polymorphisms, leading to variations in drug metabolism rates among individuals. These genetic differences can result in four distinct phenotypes: poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM), and ultra-rapid metabolizers (UM).

Poor metabolizers have decreased or absent CYP2D6 enzyme activity due to genetic mutations, leading to an accumulation of drugs in the body and increased susceptibility to adverse drug reactions. In contrast, ultra-rapid metabolizers possess multiple copies of the functional CYP2D6 gene, resulting in enhanced enzymatic activity and rapid drug clearance. This can lead to therapeutic failure due to insufficient drug exposure at the target site.

Understanding the genetic variations in CYP2D6 is essential for personalized medicine, as it allows healthcare providers to tailor drug therapy based on an individual's metabolic capacity and minimize the risk of adverse reactions or treatment failures.

Disopyramide is an antiarrhythmic medication that is primarily used to treat certain types of irregular heart rhythms (arrhythmias), such as ventricular tachycardia and atrial fibrillation. It works by blocking the activity of sodium channels in the heart, which helps to slow down and regulate the heart rate.

Disopyramide is available in immediate-release and extended-release forms, and it may be taken orally as a tablet or capsule. Common side effects of this medication include dry mouth, blurred vision, constipation, and difficulty urinating. More serious side effects can include dizziness, fainting, irregular heartbeat, and allergic reactions.

It is important to take disopyramide exactly as directed by a healthcare provider, as improper use or dosing can lead to serious complications. Additionally, individuals with certain medical conditions, such as heart failure, kidney disease, or myasthenia gravis, may not be able to safely take this medication.

Flecainide is an antiarrhythmic medication used to regularize abnormal heart rhythms, specifically certain types of irregular heartbeats called ventricular arrhythmias and paroxysmal atrial tachycardia/atrial fibrillation. It works by blocking sodium channels in the heart, which helps to slow down the conduction of electrical signals and reduces the likelihood of erratic heart rhythms.

Flecainide is available in oral forms such as tablets or capsules and is typically prescribed under the supervision of a healthcare professional experienced in managing heart rhythm disorders. It's important to note that flecainide can have serious side effects, including increasing the risk of dangerous arrhythmias in some patients, so it should only be used under close medical monitoring.

This definition is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. If you have any questions about your medications or health conditions, please consult with your healthcare provider.

Cinchona alkaloids are a group of naturally occurring chemical compounds that are found in the bark of Cinchona trees, which are native to South America. These alkaloids have been used for centuries in traditional medicine to treat various ailments, most notably malaria. The main cinchona alkaloids include quinine, quinidine, cinchonine, and cinchonidine.

Quinine is the most well-known of these alkaloids and has been used for centuries as an effective antimalarial agent. It works by interfering with the reproduction of the malaria parasite in the red blood cells. Quinine is also used to treat other medical conditions, such as leg cramps and restless legs syndrome.

Quinidine is another important cinchona alkaloid that is used primarily as an antiarrhythmic agent to treat irregular heart rhythms. It works by slowing down the electrical conduction in the heart and stabilizing its rhythm.

Cinchonine and cinchonidine have more limited medical uses, mainly as bitter-tasting ingredients in tonics and other beverages. However, they also have some medicinal properties, such as being used as antimalarial agents and antiarrhythmic drugs in some countries.

It is important to note that cinchona alkaloids can have serious side effects if not used properly, so they should only be taken under the supervision of a healthcare professional.

Dextromethorphan is a medication that is commonly used as a cough suppressant in over-the-counter cold and cough remedies. It works by numbing the throat area, which helps to reduce the cough reflex. Dextromethorphan is a synthetic derivative of morphine, but it does not have the same pain-relieving or addictive properties as opioids.

Dextromethorphan is available in various forms, including tablets, capsules, liquids, and lozenges. It is often combined with other medications, such as antihistamines, decongestants, and pain relievers, to provide relief from cold and flu symptoms.

While dextromethorphan is generally considered safe when used as directed, it can have side effects, including dizziness, drowsiness, and stomach upset. In high doses or when taken with certain other medications, dextromethorphan can cause hallucinations, impaired judgment, and other serious side effects. It is important to follow the recommended dosage and to talk to a healthcare provider before taking dextromethorphan if you have any health conditions or are taking other medications.

Oxidoreductases, O-demethylating are enzymes that belong to the larger family of oxidoreductases. Specifically, they are involved in catalyzing the removal of methyl groups (-CH3) from various substrates through oxidation reactions. This process is known as O-demethylation.

These enzymes play a crucial role in the metabolism of xenobiotics (foreign substances) such as drugs, toxins, and carcinogens. They help convert these substances into more water-soluble forms, which can then be easily excreted from the body. O-demethylating oxidoreductases are often found in the liver, where they contribute to the detoxification of xenobiotics.

The reaction catalyzed by these enzymes involves the transfer of a hydrogen atom and the addition of an oxygen atom to the methyl group, resulting in the formation of formaldehyde (-CH2O) and a demethylated product. The cytochrome P450 family of enzymes is one example of O-demethylating oxidoreductases.

Propafenone is an antiarrhythmic medication used to treat certain types of irregular heartbeats (such as atrial fibrillation, paroxysmal supraventricular tachycardia). It works by blocking certain electrical signals in the heart to help it beat regularly. Propafenone belongs to a class of drugs known as Class IC antiarrhythmics.

It is important to note that this definition provides an overview of what propafenone is and how it is used, but it does not cover all possible uses, precautions, side effects, and interactions related to the drug. For more detailed information about propafenone, including its specific indications, contraindications, and potential adverse effects, consult a reliable medical reference or speak with a healthcare professional.

Sparteine is not typically referred to as a "medical definition" in the context of modern medicine. However, it is a chemical compound with some historical use in medicine and a well-defined chemical structure.

Here's a chemical definition of sparteine:

Sparteine is an alkaloid derived from plants of the genus *Colutea* and *Genista*, but most notably from *Crotalaria sagittalis* (rattlebox) and *Echium plantagineum* (viper's bugloss). Its chemical formula is C15H24N2, and it has a molecular weight of 228.36 g/mol.

Sparteine is a stereoisomer of lupanine and is structurally related to other natural alkaloids such as nicotine and coniine. It is a chiral compound with two stereocenters, existing as four different stereoisomers: (−)-sparteine, (+)-sparteine, (−)-pseudosparteine, and (+)-pseudosparteine.

Historically, sparteine has been used in medicine as a cardiotonic, uterine stimulant, and antispasmodic. However, due to its narrow therapeutic index and the availability of safer alternatives, it is no longer in common clinical use today.

Debrisoquine is a drug that belongs to a class of medications called non-selective beta blockers. It works by blocking the action of certain natural substances in your body, such as adrenaline, on the heart and blood vessels. This results in a decrease in heart rate and blood pressure, which makes debrisoquine useful in treating certain conditions like hypertension (high blood pressure) and angina (chest pain).

Debrisoquine is no longer commonly used due to its short duration of action and the availability of more effective and safer beta blockers. It was also found that some people have a genetic variation that affects how their body metabolizes debrisoquine, which can lead to unpredictable drug levels and side effects. This discovery led to the development of the concept of "pharmacogenetics," or how genetic factors influence drug response.

It's important to note that debrisoquine should only be taken under the supervision of a healthcare professional, as it can have serious side effects, especially if not used correctly.

Lidocaine is a type of local anesthetic that numbs painful areas and is used to prevent pain during certain medical procedures. It works by blocking the nerves that transmit pain signals to the brain. In addition to its use as an anesthetic, lidocaine can also be used to treat irregular heart rates and relieve itching caused by allergic reactions or skin conditions such as eczema.

Lidocaine is available in various forms, including creams, gels, ointments, sprays, solutions, and injectable preparations. It can be applied directly to the skin or mucous membranes, or it can be administered by injection into a muscle or vein. The specific dosage and method of administration will depend on the reason for its use and the individual patient's medical history and current health status.

Like all medications, lidocaine can have side effects, including allergic reactions, numbness that lasts too long, and in rare cases, heart problems or seizures. It is important to follow the instructions of a healthcare provider carefully when using lidocaine to minimize the risk of adverse effects.

... is also used to treat short QT syndrome. Eli Lilly has discontinued manufacture of parenteral quinidine gluconate in ... Quinidine-based ligands are used in AD-mix-β for Sharpless asymmetric dihydroxylation. Quinidine sulfate is used in the ... The dose of quinidine (10mg two times daily) is about 1/40th of a relatively low antiarrhythmic dose (400mg, twice or 3 times ... Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6, and can lead to increased blood levels of lidocaine, beta ...
... dextromethorphan hydrobromide 30 mg/quinidine sulfate 10 mg (N=110) Nuedexta - dextromethorphan hydrobromide 20 mg/quinidine ... Quinidine sulfate affects the way the heart beats, and is generally used in people with certain heart rhythm disorders. It is ... Dextromethorphan/quinidine is a combination of these two generic drugs, and is the first FDA-approved drug for the treatment of ... "Quinidine sulfate". PDRhealth™. 2016. Archived from the original on 2015-09-05. Retrieved 2016-02-18. "Label: NUEDEXTA- ...
Quinidine is an antiarrhythmic drug that may reduce the chance of serious abnormal heart rhythms occurring in some people with ... Yang F, Hanon S, Lam P, Schweitzer P (April 2009). "Quinidine revisited". The American Journal of Medicine. 122 (4): 317-21. ... Belhassen B, Glick A, Viskin S (September 2004). "Efficacy of quinidine in high-risk patients with Brugada syndrome". ... while quinidine may be used longer term. Testing people's family members may be recommended. The condition affects between 1 ...
... (and quinidine) are used as the chiral moiety for the ligands used in Sharpless asymmetric dihydroxylation as well as ... No injectable preparation of quinine is licensed in the US; quinidine is used instead. Quinine is a flavor component of tonic ... Centers for Disease Control and Prevention (April 1991). "Treatment with quinidine gluconate of persons with severe Plasmodium ... September 2005). "Effects of quinine, quinidine, and chloroquine on alpha9alpha10 nicotinic cholinergic receptors". Molecular ...
... 's Class 1a activity is similar to that of quinidine in that it targets sodium channels to inhibit conduction. ... Quinidine, procainamide and disopyramide". Drug Safety. 5 (6): 393-420. doi:10.2165/00002018-199005060-00002. PMID 2285495. ... in higher doses compared to quinidine. Levites proposed a possible secondary mode of action for disopyramide, against reentrant ... "Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: ...
Dykstra SJ, Minielli JL, Lawson JE, Ferguson HC, Dungan KW (September 1973). "Lysergic acid and quinidine analogs. 2-(o- ...
Quinimax and quinidine are the two most commonly used alkaloids related to quinine in the treatment or prevention of malaria. ... Quinidine is a direct derivative of quinine. It is a distereoisomer, thus having similar anti-malarial properties to the parent ... Quinidine is recommended only for the treatment of severe cases of malaria. Warburg's tincture was a febrifuge developed by ... Quinimax is a combination of four alkaloids (quinine, quinidine, cinchonine and cinchonidine). This combination has been shown ...
Quinidine : Increased anticholinergic action (particular on AV conduction). Antipsychotics : Long term use of trihexyphenidyl ...
Quinidine : Increased anticholinergic action (particular on AV conduction). Antipsychotics : Long-term use of biperiden may ...
While procainamide and quinidine may be used in the conversion of atrial fibrillation to normal sinus rhythm, they should only ... Class Ia agents include quinidine, procainamide and disopyramide. Class Ib antiarrhythmic agents are sodium channel blockers. ... because procainamide and quinidine can increase the conduction through the AV node and may cause 1:1 conduction of atrial ...
It has a quinidine-like anti-arrhythmic effect. It has vasodilatory properties and can therefore reduce blood pressure. ...
Procainamide, quinidine and disopyramide are Class Ia agents. Class 1b drugs lengthen phase 3 repolarization. They include ...
Two more key alkaloids, quinidine and cinchonidine, were later identified and it became a routine in quinology to examine the ... The bark contains alkaloids, including quinine and quinidine. Cinchona is the only economically practical source of quinine, a ... Cinchona alkaloids include: cinchonine and cinchonidine (stereoisomers with R1 = vinyl, R2 = hydrogen) quinine and quinidine ( ...
Medications indicated for: Irregular heartbeat, e.g. disopyramide, quinidine. Drug-induced arrhythmia worsened by ...
... taken with quinidine was found to produce respiratory depression, indicative of central opioid action. High doses of ... Concurrent administration of P-glycoprotein inhibitors such as quinidine potentially allows loperamide to cross the blood-brain ... Common P-glycoprotein inhibitors include quinidine, ritonavir, and ketoconazole. Loperamide is capable of decreasing the ...
Quinidine may interact with chlorpromazine to increase myocardial depression. Likewise, it may also antagonize the effects of ... Other drugs that prolong the QT interval, such as quinidine, verapamil, amiodarone, sotalol and methadone, may also interact ...
Quinidine also increases levels of amikacin in the body. The NSAID indomethacin can increase serum aminoglycoside levels in ...
Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use". Pharmacol. Ther. 164: 170-82. doi:10.1016/j.pharmthera. ...
Due to the loss of Indonesia in World War II, the source for cinchona alkaloids, a precursor of quinidine, was reduced. This ... As a result, procaine was discovered, which has similar cardiac effects as quinidine. In 1936 it was found by Mautz that by ... These were the cardiac glycosides, quinidine, propranolol, lidocaine and diphenylhydantoin. In January 1996, extended release ... but it had the same toxicity profile as quinidine, and it could cause systemic lupus erythematosus-like syndrome. These ...
Woodhall B, Sealy WC, Hall KD, Floyd WL (July 1960). "Craniotomy under conditions of quinidine-protected cardioplegia and ... Woodhall B, Sealy WC, Hall KD, Floyd WL (July 1960). "Craniotomy under conditions of quinidine-protected cardioplegia and ... Woodhall B, Sealy WC, Hall KD, Floyd WL (July 1960). "Craniotomy under conditions of quinidine-protected cardioplegia and ...
Quinidine, reduces urinary excretion of quinidine, hence increasing the potential for toxicity. Salicylates, potential for ...
Quinidine toxicity can lead to cinchonism and also to quinine amaurosis.[citation needed] Those experiencing amaurosis are ...
Other alkaloids that are extracted from this tree include cinchonine, cinchonidine and quinidine. Standley, Paul C. (1936). " ...
Drugs such as quinidine may be both reverse use dependent and use dependent. Examples of calcium-activated potassium channel ... Reverse use dependent drugs that slow heart rate (such as quinidine) can be less effective at high heart rates. The ... such as quinidine) are more efficacious at preventing a tachyarrhythmia than converting someone into normal sinus rhythm.[ ... Bupivacaine Quinidine Fluoxetine Seproxetine (Norfluoxetine) 12-O-tetradecanoylphorbol-13-acetate (TPA) (phorbol 12-myristate ...
Protoporphyrin IX Complexes of the Antimalarial Cinchona Alkaloids Quinine and Quinidine". ACS Chemical Biology. 7 (4): 666-71 ...
April 2007). "Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally". ...
... shows membrane-stabilizing effects like quinidine, possibly accounting for its antiarrhythmic effects. It also acts as ...
... concomitant administration of fluconazole and quinidine, especially when fluconazole is administered in high dosages; take ...
... and Quinidine". Annual Review of Pharmacology and Toxicology. 16: 189-99. doi:10.1146/annurev.pa.16.040176.001201. PMID 779614 ...
Long QT syndrome Torsades de pointes Roden DM, Woosley RL, Primm RK (1986). "Incidence and clinical features of the quinidine- ... TdP is seen more frequently with therapeutic levels of quinidine. Sodium blocking activity is dominant with subtherapeutic ... blocking activity takes precedence over the sodium channel blocking activity Disopyramide Procainamide Propafenone Quinidine ...
Quinidine is also used to treat short QT syndrome. Eli Lilly has discontinued manufacture of parenteral quinidine gluconate in ... Quinidine-based ligands are used in AD-mix-β for Sharpless asymmetric dihydroxylation. Quinidine sulfate is used in the ... The dose of quinidine (10mg two times daily) is about 1/40th of a relatively low antiarrhythmic dose (400mg, twice or 3 times ... Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6, and can lead to increased blood levels of lidocaine, beta ...
Quinidine (Disontinued Brands: Cardioquine, Cin-Quin, Duraquin, Quinidex, Quinora, Quinact) is an antiarrhythmic medication ... Cimetidine (Tagamet) increases quinidine levels by decreasing the elimination of quinidine giving rise to elevated quinidine ... should not be used with quinidine since their concomitant use can increase quinidine levels by inhibiting removal of quinidine ... Quinidine is an antiarrhythmic agent and antimalarial drug.. Is quinidine available as a generic drug?. GENERIC AVAILABLE: Yes ...
QUINIDINE GLUCONATE (quinidine gluonate) tablet, extended release. NDC Code(s): 71930-016-12 *Packager: Eywa Pharma Inc ... quinidine gluconate (Quinidine Gluconate) tablet, extended release. NDC Code(s): 0591-5538-01, 0591-5538-05, 0591-5538-25 * ... QUINIDINE GLUCONATE tablet, extended release. NDC Code(s): 54738-901-01, 54738-901-02 *Packager: Richmond Pharmaceuticals, Inc. ... QUINIDINE GLUCONATE tablet, extended release. NDC Code(s): 53489-141-01, 53489-141-03, 53489-141-05, 53489-141-06, view more ...
Dextromethorphan and quinidine combination is used to treat a rare condition called pseudobulbar affect (PBA) or emotional ...
For irregular heartbeat. Generic Name: Quinidine Sulfate.
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, ... and quinidine (Q) in patients with painful DPN. A secondary objective was to perform a preliminary assessment of the efficacy ...
Oxidation of quinidine by human liver cytochrome P-450.. F P Guengerich, D Müller-Enoch and I A Blair ... Oxidation of quinidine by human liver cytochrome P-450.. F P Guengerich, D Müller-Enoch and I A Blair ... Oxidation of quinidine by human liver cytochrome P-450.. F P Guengerich, D Müller-Enoch and I A Blair ... Oxidation of quinidine by human liver cytochrome P-450. Message Subject (Your Name) has forwarded a page to you from Molecular ...
Comparison of a spectro fluorometric method with a gas liquid chromatographic procedure for the determination of quinidine ... Moulin, M.A.; Kinsun, H. 1977: A gas-liquid chromatographic method for the quantitative determination of quinidine in blood ... Ace, L N.; Chaudhuri, B 1987: Improved Liquid-Chromatographic Determination of Quinidine in Plasma Analytical Letters 20(9): ... Kates, R.E.; McKennon, D.W.; Comstock, T.J. 1978: Rapid high-pressure liquid chromatographic determination of quinidine and ...
Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine. Kirk M. ... In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation- ... Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine. Kirk M. ... Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine. Kirk M. ...
We use cookies to ensure that we give you the best experience on our website. If you click Accept all cookies well assume that you are happy to receive all cookies and you wont see this message again. If you click Reject all non-essential cookies only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click Find out more for information on how to change your cookie settings. ...
Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances. ... Quinidine Explained. Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances.[1] It is a ... Quinidine is also used to treat short QT syndrome.[5]. Eli Lilly has discontinued manufacture of parenteral quinidine gluconate ... Quinidine acts as a blocker of voltage-gated sodium channels.[12] [13] Inhibition of the Nav1.5 channel is specifically ...
QUINIDINE GLUCONATE. QUINIDINE GLUCONATE. 324MG. TABLET, EXTENDED RELEASE;ORAL. Prescription. No. AB. 089338 SUN PHARM ... QUINIDINE GLUCONATE. QUINIDINE GLUCONATE. 324MG. TABLET, EXTENDED RELEASE;ORAL. Prescription. No. AB. 212589. EYWA ... QUINIDINE GLUCONATE. QUINIDINE GLUCONATE. 324MG. TABLET, EXTENDED RELEASE;ORAL. Prescription. AB. No. Yes. ...
Quinidine Sulfate is by Carilion Materials Management. The product is distributed in a single package with NDC code 68151-1991- ... RxCUI: 852877 - quinidine sulfate 200 MG Oral Tablet. *RxCUI: 852877 - quinidine sulfate 200 MG (quinidine 166 MG) Oral Tablet ... Which are Quinidine Sulfate UNII Codes?. The UNII codes for the active ingredients in this product are:. *QUINIDINE SULFATE ( ... NDC Product Code: 68151-1991 Quinidine Sulfate. NDC 68151-1991 Quinidine Sulfate. View Dosage, Usage, Ingredients, Routes, UNII ...
Quinidine answers are found in the Johns Hopkins ABX Guide powered by Unbound Medicine. Available for iPhone, iPad, Android, ... "Quinidine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/ ... view/Johns_Hopkins_ABX_Guide/540465/9/Quinidine. Avdic E. Quinidine. Johns Hopkins ABX Guide. The Johns Hopkins University; ... IV quinidine gluconate*No longer manufactured in the U.S. *The manufacturer plans to continue distributing the product until ...
Quinidine gluconate can be administered IV and is the only parenterally available quinine derivative in the United States. ... Quinidine gluconate is indicated for severe or complicated malaria and is used in conjunction with doxycycline, tetracycline, ... Clindamycin is part of combination therapy for drug-resistant malaria (eg, typically with quinine or quinidine). It is a good ...
Round and has been identified as Quinidine Sulfate 200 mg. It is supplied by Watson Pharmaceuticals. ... Quinidine Sulfate. Imprint. 5438 DAN DAN. Strength. 200 mg. Color. White. Shape. Round. Availability. Prescription only. Drug ... Quinidine is used in the treatment of Malaria; Arrhythmia and belongs to the drug class group I antiarrhythmics. Risk cannot be ... Pill with imprint 5438 DAN DAN is White, Round and has been identified as Quinidine Sulfate 200 mg. It is supplied by Watson ...
Find information on Quinidine (Quinaglute, Quinidex) in Daviss Drug Guide including dosage, side effects, interactions, ... "QUINIDINE." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/ ... view/Davis-Drug-Guide/51653/0/QUINIDINE. Vallerand AHA, Sanoski CAC, Quiring CC. QUINIDINE. Daviss Drug Guide. F.A. Davis ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). QUINIDINE. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ...
Other medications can affect the removal of quinidine from your body, which may affect how quinidine works. Examples include ... Quinidine may also be used to treat malaria.. HOW TO USE: Before starting this drug, the manufacturer recommends that you take ... Do not change quinidine products without talking to your doctor or pharmacist. Dosage is based on your medical condition and ... PRECAUTIONS: Before taking quinidine, tell your doctor or pharmacist if you are allergic to it; or to quinine; or if you have ...
Find information on Quinidine (Quinaglute, Quinidex) in Daviss Drug Guide including dosage, side effects, interactions, ... www.drugguide.com/ddo/view/Davis-Drug-Guide/51653/all/QUINIDINE. Vallerand AHA, Sanoski CAC, Quiring CC. QUINIDINE. Daviss ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). QUINIDINE. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ... TY - ELEC T1 - QUINIDINE ID - 51653 A1 - Sanoski,Cynthia A, AU - Vallerand,April Hazard, AU - Quiring,Courtney, BT - Daviss ...
NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) HCC Treatment Paying for treatment. If youre prescribed NUEDEXTA, its ...
Quinidine Sulfate Suspension 10 mg/mL-Formulation 2 published on Jan 2022 by ASHP. ...
We have identified six cases of quinidine-induced immune thrombocytopenia based on clinical evidence and in association with ... We have identified six cases of quinidine-induced immune thrombocytopenia based on clinical evidence and in association with ... Saleh, Mansoor N.; Dhodaphar, Nadhav; Allen, Karen; and LoBuglio, Albert F. (1989) "Quinidine-Induced Immune Thrombocytopenia ...
267 mg of quinidine gluconate = 275 mg of quinidine polygalacturonate = 200 mg of quinidine sulfate. ) ... Quinidine Dosing (adults): Antiarrhythmic: (Oral) Sulfate: 100-600 mg/dose every 4-6 hours; begin at 200 mg/dose and titrate to ... Treatment with Class I or III antiarrhythmics (e.g., amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, ...
Gastroenteritis is a nonspecific term for various pathologic states of the gastrointestinal tract. The primary manifestation is diarrhea, but it may be accompanied by nausea, vomiting, and abdominal pain.
... quinidine; sedatives; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), ...
quinidine. *procainamide. *tricyclic antidepressants such as amitriptyline, desipramine (Norpramin), and imipramine (Tofranil) ...
Leukopenia is a condition where a person has a reduced number of white blood cells and an increased risk of infection. Learn more.
... verapamil or quinidine co-administration ... quinidine. 2D6 strong inhibitor. P-gp inhibitor. R-venlafaxine ...
  • Eli Lilly has discontinued manufacture of parenteral quinidine gluconate in the US, and its future availability in many countries is uncertain. (wikipedia.org)
  • For adults, the dosage range for quinidine gluconate is from 648 to 2592 mg/day. (medicinenet.com)
  • Quinidine gluconate is indicated for severe or complicated malaria and is used in conjunction with doxycycline, tetracycline, or clindamycin. (medscape.com)
  • Quinidine gluconate can be administered IV and is the only parenterally available quinine derivative in the United States. (medscape.com)
  • The evaluation was requested by the local union to investigate work related skin rashes and respiratory symptoms among employees involved in producing quinidine-gluconate (7054253). (cdc.gov)
  • Background-- Quinidine gluconate, the only FDA-approved treatment for life-threatening malaria in the United States, has a problematic safety profile and is often unavailable in hospitals. (cdc.gov)
  • Plasma samples, obtained at different time intervals after administration of single doses of quinidine sulfate to healthy human volunteers and to a dog, were analyzed by both procedures. (eurekamag.com)
  • The NDC code 68151-1991 is assigned by the FDA to the product Quinidine Sulfate which is product labeled by Carilion Materials Management. (ndclist.com)
  • Which are Quinidine Sulfate UNII Codes? (ndclist.com)
  • What is the NDC to RxNorm Crosswalk for Quinidine Sulfate? (ndclist.com)
  • Pill with imprint 5438 DAN DAN is White, Round and has been identified as Quinidine Sulfate 200 mg. (drugs.com)
  • Although intravenous quinidine is sometimes used to treat Plasmodium falciparum malaria, the future availability of this agent is uncertain. (wikipedia.org)
  • Quinidine also is used to treat malaria . (medicinenet.com)
  • The pharmacokinetics of quinine and quinidine in malaria. (tropmedres.ac)
  • When it is administered for treatment of P falciparum malaria, this drug must be used as part of combination therapy (eg, typically with quinine or quinidine). (medscape.com)
  • Clindamycin is part of combination therapy for drug-resistant malaria (eg, typically with quinine or quinidine). (medscape.com)
  • Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. (ox.ac.uk)
  • We recorded electrocardiograms from 31 patients receiving quinine and 14 patients receiving quinidine for the treatment of Plasmodium falciparum malaria. (ox.ac.uk)
  • An antibiotic that can be used for the treatment of malaria in combination with a second drug, usually quinine or quinidine. (cdc.gov)
  • Quinidine is used to treat abnormal heart rhythms and malaria. (rxwiki.com)
  • Protocol eligibility required the presence of microscopically confirmed malaria, the need for intravenous treatment, and an impediment to quinidine. (cdc.gov)
  • The only FDA-approved treatment for severe malaria in the United States is quinidine, a stereoisomer of quinine that once saw routine hospital use as a Author Manuscript cardiac anti-arrhythmic medication (11, 12). (cdc.gov)
  • Dextromethorphan and quinidine combination is used to treat a rare condition called pseudobulbar affect (PBA) or emotional incontinence. (mayoclinic.org)
  • The primary objective of this study was to evaluate the tolerability of capsules containing dextromethorphan (DM) and quinidine (Q) in patients with painful DPN. (nih.gov)
  • At micromolar concentrations, quinidine inhibits Na+/K+-ATPase by binding to the same receptor sites as the digitalis glycosides such as ouabain. (wikipedia.org)
  • An improved spectrofluorometric method was compared with a recently published GLC procedure for the determination of plasma concentrations of quinidine [an antiarrhythmic agent]. (eurekamag.com)
  • The results suggested that the overall binding of quinidine is relatively insensitive to changes in any one serum protein provided the others are present in normal concentrations. (bvsalud.org)
  • Airborne quinidine concentrations ranged from 0.2 milligram per cubic meter (mg/m3) in the packaging area to 5.0mg/m3 in the manufacturing area. (cdc.gov)
  • Blood levels of digoxin ( Lanoxin ) are raised by quinidine due to a reduction in removal or reduced distribution in the body of digoxin. (medicinenet.com)
  • Side effects from quinine or quinidine. (cdc.gov)
  • by itself for prevention or in combination with either quinine or quinidine when used for treatment. (cdc.gov)
  • Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances. (wikipedia.org)
  • Here we present the cryo-EM structure of full-length human Na 1.5 bound to quinidine, a class Ia antiarrhythmic drug, at 3.3 Å resolution. (princeton.edu)
  • Procainamide and quinidine also have been listed here for completeness and because they are used by many neurologists to treat muscle stiffness and muscle spasm. (medscape.com)
  • Even when quinidine can be obtained, its intravenous regimen is complex, and its dosing fraught with safety concerns. (cdc.gov)
  • Many heart drugs like quinidine (antiarrhythmics) are very effective, but they can infrequently cause new serious (possibly fatal) irregular heartbeats. (healthwarehouse.com)
  • Quinidine belongs to a group of drugs called antiarrhythmics. (rxwiki.com)
  • Quinidine is an antiarrhythmic drug used in the treatment of abnormal heart rhythms such as atrial fibrillation , atrial flutter , and ventricular arrhythmias such as paroxysmal ventricular tachycardia. (medicinenet.com)
  • With the exact mechanism not known, amiodarone ( Cordarone ), another type of antiarrhythmic drug, may decrease removal of quinidine by the kidneys or liver giving rise to elevated quinidine blood levels, which may result in life-threatening arrhythmias, including torsades de pointes. (medicinenet.com)
  • Removal of quinidine by the liver is accelerated by phenobarbital, phenytoin ( Dilantin ), and rifampin ( Rifamate ), requiring an increase in quinidine dose. (medicinenet.com)
  • Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6, and can lead to increased blood levels of lidocaine, beta blockers, opioids, and some antidepressants. (wikipedia.org)
  • The elimination half-life of oral quinidine is 6 to 8 hours, and it is eliminated by the cytochrome P450 system in the liver. (wikipedia.org)
  • Oxidation of quinidine by human liver cytochrome P-450. (aspetjournals.org)
  • Quinidine is an antiarrhythmic agent and antimalarial drug. (medicinenet.com)
  • Quinidine, the only FDA-approved IV antimalarial drug, will no longer be available starting April 1, 2019. (cdc.gov)
  • Quinidine can cause thrombocytopenia, granulomatous hepatitis, myasthenia gravis, and torsades de pointes (dangerous heart rhythm), so is not used much today. (wikipedia.org)
  • Quinidine-induced thrombocytopenia (low platelet count) is mediated by the immune system, and may lead to thrombocytic purpura. (wikipedia.org)
  • Quinidine-Induced Immune Thrombocytopenia" by Mansoor N. Saleh, Nadhav Dhodaphar et al. (henryford.com)
  • We have identified six cases of quinidine-induced immune thrombocytopenia based on clinical evidence and in association with elevated amounts of platelet surface IgG. (henryford.com)
  • Do not crush or chew quinidine tablets. (rxwiki.com)
  • 2023. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/51653/0/QUINIDINE. (unboundmedicine.com)
  • 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51653/all/QUINIDINE. (drugguide.com)
  • Quinidine also inhibits the transport protein P-glycoprotein and so can cause some peripherally acting drugs such as loperamide to have central nervous system side effects, such as respiratory depression, if the two drugs are coadministered. (wikipedia.org)
  • Quinidine can greatly improve your ability to perform normal activities by decreasing the number of irregular heartbeats you have. (ndclist.com)
  • If you are taking regular-release quinidine for an irregular heartbeat, the manufacturer recommends that you take no more than 4 grams daily. (healthwarehouse.com)
  • Quinidine intoxication can lead to a collection of symptoms collectively known as cinchonism, with tinnitus (ringing in the ears) being among the most characteristic and common symptoms of this toxicity syndrome. (wikipedia.org)
  • Increased quinidine levels can increase the risk of quinidine toxicity and cardiac arrhythmias. (medicinenet.com)
  • Cimetidine ( Tagamet ) increases quinidine levels by decreasing the elimination of quinidine giving rise to elevated quinidine serum levels that may lead to quinidine toxicity. (medicinenet.com)
  • Azole antifungals such as ketoconazole ( Nizoral ), fluconazole ( Diflucan ), itraconazole ( Sporanox PulsePak), voriconazole ( VFEND ), posaconazole (Noxafil), and protease inhibitor /antiretroviral drugs such as indinavir ( Crixivan ), and saquinavir ( Invirase ) should not be used with quinidine since their concomitant use can increase quinidine levels by inhibiting removal of quinidine by the liver . (medicinenet.com)
  • In addition to having a substantial adverse event profile quinidine can react with many concomitant medications, requiring dosage adjustments and careful monitoring, typically in an Intensive Care Unit (ICU) setting (15-17). (cdc.gov)
  • Which drugs or supplements interact with quinidine? (medicinenet.com)
  • The anticholinergic effect of drugs such as tri- and tetracyclic antidepressants, antihistamines, quinidine, amantadine, antipsychotics (e.g. butyrophenones, phenothiazines), disopyramide and other anticholinergics (e.g. tiotropium, ipratropium, atropine-like compounds) may be intensified by Buscopan. (janusinfo.se)
  • It is important, therefore, to decrease quinidine doses when it is given concomitantly with amiodarone . (medicinenet.com)
  • In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. (aspetjournals.org)
  • These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine. (aspetjournals.org)
  • The authors did not observe significant safety risks using the low quinidine dose, but urged caution and also pointed out that quinidine interacts with a large number of other medications in dangerous or unpredictable ways. (wikipedia.org)
  • Before and while you are using quinidine, your doctor may prescribe other medications (e.g., "blood thinners"/anticoagulants such as warfarin, beta blockers such as metoprolol) to shrink any blood clots in the heart and to slow your pulse. (ndclist.com)
  • Eating grapefruit or drinking grapefruit juice may increase the amount of certain medications in your bloodstream, including quinidine. (healthwarehouse.com)
  • Quinidine is occasionally used as a class I antiarrhythmic agent to prevent ventricular arrhythmias, particularly in Brugada Syndrome, although its safety in this indication is uncertain. (wikipedia.org)
  • Phenothiazines such as thioridazine (Mellaril), an antipsychotic drug, and tricyclic antidepressants such as amitriptyline ( Elavil , Endep ) should not be used with quinidine since they can cause cardiac arrhythmias, and their use with quinidine increases the risk of cardiac arrhythmias. (medicinenet.com)
  • Conclusions: High AFR is associated with failure of quinidine cardioversion and AF recurrence after successful TVEC. (lu.se)
  • Conclusions-- Artesunate was a safe and clinically beneficial alternative to quinidine. (cdc.gov)
  • As a noninvasive marker that can be retrieved from surface ECG, AFR can be clinically useful in predicting the probability of responding to quinidine treatment as well as maintaining SR after electrical cardioversion. (lu.se)
  • The effect of quinidine on the ion channels is to prolong the cardiac action potential, thereby prolonging the QT interval on the surface ECG. (wikipedia.org)
  • The effects of cinchona bark (the botanical source from which quinidine is extracted) had been commented on long before the understanding of cardiac physiology arose. (wikipedia.org)
  • Plasma samples from patients treated with quinidine were also analyzed by both procedures. (eurekamag.com)
  • QT prolongation was considerably greater in the quinidine-treated patients. (ox.ac.uk)
  • Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias. (bvsalud.org)
  • Evaluation of the degree of protein binding of quinidine in plasma from normal subjects and patients with types IV and IIa hyperlipoproteinemias supported the computer predictions. (bvsalud.org)
  • The quinidine binding in plasma of patients with hyperlipoproteinemias did not differ statistically from that in the normal subjects. (bvsalud.org)
  • Methods: Electrocardiograms (ECG) from horses with persistent AF admitted for cardioversion with either medical treatment (quinidine) or transvenous electrical cardioversion (TVEC) were included. (lu.se)
  • Results: Of the 195 horses included, 74 received quinidine treatment and 121 were treated with TVEC. (lu.se)
  • Common side effects of quinidine include diarrhea, lightheadedness, and headache. (rxwiki.com)
  • Quinidine increases the action of the blood thinner warfarin ( Coumadin , Jantoven ), due to synergistic effects and can lead to excessive blood thinning and bleeding. (medicinenet.com)
  • Quinidine is also used to treat short QT syndrome. (wikipedia.org)
  • Quinidine is a prescription medication used to treat abnormal heart rhythms. (rxwiki.com)
  • Is quinidine safe to take if I'm pregnant or breastfeeding? (medicinenet.com)
  • Safety and efficacy of quinidine has not been established in pregnant women. (medicinenet.com)
  • Quinidine in the plasma binds to various lipoproteins as well as to albumin . (bvsalud.org)

No images available that match "quinidine"